Scandion Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Scandion Oncology wird ein jährliches Gewinn- und Umsatzwachstum von 75.3% bzw. 40.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 92.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 23.7% betragen.

Wichtige Informationen

75.3%

Wachstumsrate der Gewinne

92.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	49.5%
Wachstumsrate der Einnahmen	40.7%
Zukünftige Eigenkapitalrendite	23.7%
Analystenabdeckung	Low
Zuletzt aktualisiert	29 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Aug 02

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Feb 01

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

May 26

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

Jan 06

Gewinn- und Umsatzwachstumsprognosen

OM:SCOL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (DKK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-3	-3	-3	1
12/31/2025	49	23	23	23	1
12/31/2024	N/A	-27	-23	-23	1
6/30/2024	N/A	-36	-33	-33	N/A
3/31/2024	N/A	-37	-43	-43	N/A
12/31/2023	N/A	-39	-51	-51	N/A
9/30/2023	N/A	-44	-54	-54	N/A
6/30/2023	N/A	-59	-69	-69	N/A
3/31/2023	N/A	-73	-69	-69	N/A
12/31/2022	N/A	-77	-70	-69	N/A
9/30/2022	N/A	-76	-68	-67	N/A
6/30/2022	N/A	-66	-57	-57	N/A
3/31/2022	N/A	-56	-57	-56	N/A
12/31/2021	N/A	-52	-50	-50	N/A
9/30/2021	N/A	-43	-48	-48	N/A
6/30/2021	N/A	-31	-34	-34	N/A
3/31/2021	N/A	-22	-24	-24	N/A
12/31/2020	N/A	-17	-17	-17	N/A
9/30/2020	N/A	-11	-8	-8	N/A
6/30/2020	N/A	-14	-14	-14	N/A
3/31/2020	N/A	-14	-12	-12	N/A
12/31/2019	N/A	-12	-10	-10	N/A
9/30/2019	N/A	-17	-21	-21	N/A
6/30/2019	N/A	-12	-16	-16	N/A
3/31/2019	N/A	-10	-15	-15	N/A
12/31/2018	N/A	-8	-13	-13	N/A
9/30/2018	N/A	-4	-3	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SCOL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (1.2%).

Ertrag vs. Markt: SCOL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: SCOL wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: SCOLDie Einnahmen des Unternehmens (40.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (0.04% pro Jahr).

Hohe Wachstumseinnahmen: SCOLDie Einnahmen des Unternehmens (40.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SCOLDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (23.7%)

Scandion Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 81% to kr0.60

Price target decreased by 13% to kr2.80

Forecast to breakeven in 2024

Price target decreased by 31% to kr3.40

Forecast to breakeven in 2024

Price target increased by 27% to kr4.95

Recent updates

Price target decreased by 81% to kr0.60

Scandion Oncology (Scandion) Announces Topline Data for the Corist Part 3

New major risk - Shareholder dilution

New major risk - Financial position

Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial

New major risk - Revenue and earnings growth

Scandion Oncology A/S to Report Q3, 2024 Results on Nov 27, 2024

New major risk - Market cap size

Scandion Oncology Reports Positive Topline Phase IIa Data from the CORIST Part 3 Trial

Scandion Oncology A/S, Annual General Meeting, Apr 24, 2024

Scandion Oncology Receives Notice of Allowance for Patent to Enhance US Patent Exclusivity on SCO-101

Price target decreased by 13% to kr2.80

Scandion Oncology Announces Positive Data from Part 2 of its International Multi-Center CORIST Open Label Phase IIa Trial

Scandion Oncology Successfully Completes Phase Ib Pantax Trial Is and Establishes the Maximal Tolerated Dose with Positive Safety Profile and Pharmacokinetic Data

Scandion Oncology A/S Appoints Lars Damstrup, MD, PhD, as Chief Medical Officer

Scandion Oncology A/S Announces Data from PANTAX Trial to Be Presented At ESMO Congress 2023

The European Patent Office Announces Intention to Grant of Composition-Of-Matter Patent for Scandion Oncology's Lead Compound SCO-101

Forecast to breakeven in 2024

Price target decreased by 31% to kr3.40

Forecast to breakeven in 2024

Price target increased by 27% to kr4.95

Scandion Oncology Receives Opinion from the European Patent Office on Composition of Matter Patent-Application for Lead Compound SCO-101

Scandion Oncology Appoints Jan Stenvang, Ph.D., Chief Scientific Officer and Member of Executive Management

Forecast to breakeven in 2024

Scandion Oncology Appoints Francois Martelet as New Chief Executive Officer, Effective from January 2, 2023

Scandion Oncology A/S to Report Fiscal Year 2022 Results on Mar 22, 2023

Consensus revenue estimates fall by 63%

Price target decreased to kr3.90

High number of new and inexperienced directors

Scandion Oncology Initiates Part 3 of CORIST Phase II Trial Studying Scandion’s Lead Compound SCO-101 as Combination Treatment in Patients with Metastatic Colorectal Cancer

Scandion Oncology Announce Topline Results from Part 2 of the Corist Phase II Trial

Scandion Oncology A/S Announces CEO Changes

Scandion Oncology Announces Change to Its Executive Management

Scandion Oncology A/S Receives Approvals for Next Parts of the Corist Trial

Scandion Oncology Extends PANTAX Trial Due to Better-Than-Expected Tolerability of SCO-101

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Consensus forecasts updated

Consensus forecasts updated

Scandion Oncology Announces Resignation of Thomas Feldthus from the Board of Directors

Scandion Oncology A/S Announces Chief Medical Officer Change

Price target increased to kr26.00

High number of new and inexperienced directors

Scandion Oncology A/S Expands Clinical Development with Internationalization of the CORIST-Trial

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Scandion Oncology A/S Announces That Data from CORIST-Trial to Be Presented At ASCO Gastrointestinal Cancers Symposium

Scandion Oncology Receives Approval for Initiating the CORIST Part 2 Trial

Scandion Oncology Receives German Trial Approval for PANTAX Ib Study

Chief Financial Officer Carit Andersen has left the company

Alligator Bioscience AB and Scandion Oncology A/S Present Promising Preclinical Data

Scandion Oncology A/S Reports Positive Interim Results from the Corist Phase II Study

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

Scandion Oncology Appoints Dr. Maj Hedtjärn as COO and Head of R&D Operations

Scandion Oncology A/S Adjusts the Pantax Pancreatic Cancer Study

Scandion Oncology A/S Finalizes the First 12 Patients in CORIST Study

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

New 90-day low: kr22.20

New 90-day low: kr34.30

New 90-day low: kr35.00

Scandion Oncology A/S Announces Modified Timelines for Clinical Studies

Scandion Oncology A/S Receives Final Approval from the Danish Medicines Agency and Ethical Committee for Start of A Clinical Trial in Patients with Pancreatic Cancer

Scandion Oncology Appoints Bo Rode Hansen as President, Effective October 1, 2020

An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken